Strategic-Technological Analysis: MyoSwiss AG
The MyoSwiss AG story begins in 2017, when two Swiss researchers at ETH Zurich’s Sensory-Motor Systems Lab applied robotics and textile innovation to human mobility. Their flagship Myosuit is a lightweight, garment-style exoskeleton that adds a wearable layer of robotic muscle to a user’s legs. As a medical device now CE-certified and marketed in Europe[1][2], it has drawn notice beyond the rehabilitation community. But MyoSwiss’s technology – soft, sensory-controlled actuation that eases leg load – also intersects with emerging defense concerns. European planners eye advanced human-extension systems as one element of future dismounted capability. In an age of contested supply chains and multi-domain operations, a European-built wearable augmentor could both empower individual mobility and reduce reliance on non-allied tech sources. MyoSwiss lies at this nexus: a European spin-off pushing bio-robotic innovation, whose developments could influence both healthcare and soldier support. This report delves into MyoSwiss’s legal and organizational footprint, technology suite and readiness, and its place in EU/NATO innovation ecosystems. Readers will gain an authoritative, objective view of how MyoSwiss fits into Europe’s strategic autonomy puzzle – a preview of the in-depth analysis available by subscription.